El mercado de biomarcadores del cáncer se valoró en 18.436,36 millones de dólares en 2022 y es probable que llegue a EE.UU. $ 34.857,12 millones para 2028 y se estima que crecerá a una tasa compuesta anual del 11,1% durante 2022-2028
Biomarcador, una molécula biológica, que se encuentra en la sangre, los tejidos u otros fluidos corporales y es un signo de un proceso estándar o anormal. Un biomarcador se utiliza para ver qué tan bien responde el cuerpo a un tratamiento para una enfermedad o afección.
Perspectivas del mercado
Los lanzamientos de nuevos productos y las aprobaciones de la FDA junto con los avances tecnológicos impulsan el crecimiento del mercado
Los actores del mercado están fabricando una amplia gama de biomarcadores de cáncer que ofrecen las máximas ventajas y un diagnóstico precoz. En abril de 2021, Amgen lanzó Biomarker Assist, un programa para ayudar a más pacientes con cáncer de pulmón de células no pequeñas (CPCNP) metastásico (estadio IV) a obtener acceso a pruebas de biomarcadores. Las pruebas de biomarcadores en el momento del diagnóstico son un primer paso fundamental para que los pacientes reciban el tratamiento adecuado. A través de Biomarker Assist, los pacientes elegibles pueden ahorrar en pruebas de biomarcadores.
Además, En marzo de 2022, Vela Diagnostics lanzó nuevos paneles basados en secuenciación de próxima generación (NGS) enfocados (60 genes) e integrales (525 genes) para detectar biomarcadores de cáncer de ARN y ADN a partir de muestras de tejido fijadas con formalina e incluidas en parafina (FFPE). Los nuevos paneles genéticos contra el cáncer incluyen el panel OncoKey SL 60 Plus enfocado y el completo panel OncoKey SL 525 Plus.
Además, en diciembre de 2021, BioGenex lanzó tres nuevos anticuerpos de inmunohistoquímica primaria (IHC), incluidos CD8A, CD163 y CD56, para el diagnóstico del cáncer.
Además, los avances recientes en inmunoterapias contra el cáncer han surgido en respuestas clínicas duraderas en los pacientes. Las inmunoterapias contra el cáncer están reemplazando rápidamente los estándares de tratamiento tradicionales y ampliando el panorama terapéutico para los pacientes con cáncer. Los investigadores se centran en encontrar moléculas en la sangre que puedan indicar la aparición de cánceres. Para el diagnóstico de cánceres de ovario y próstata, el antígeno canceroso (CA)125 y el antígeno prostático específico (PSA) se utilizan junto con otras pruebas.
Además, los avances en las tecnologías ómicas de alto rendimiento, incluidas la genómica, la proteómica, la transcriptómica y la metabolómica, aceleraron el ritmo del descubrimiento de biomarcadores. Recientemente, el concepto de identificar el ADN tumoral circulante mediante una biopsia líquida ha pasado a la realidad clínica. La Sociedad de Inmunoterapia del Cáncer (SITC) volvió a convocar biomarcadores para un grupo de trabajo inmunológico para revisar las tecnologías de vanguardia, identificar los obstáculos actuales y hacer recomendaciones para el campo. Por lo tanto, los avances tecnológicos recientes han permitido muchos biomarcadores potenciales y renovado en el desarrollo de nuevos biomarcadores e impulsado el crecimiento de mercado de biomarcadores del cáncer
< strong>Perspectivas estratégicas
Perspectivas del mercado - Oportunidades
Mercados emergentes en países en desarrollo brindará oportunidades lucrativas al mercado durante el período de pronóstico
Emergente Mercados como Asia Pacífico están creando amplias oportunidades para que los actores importantes del mercado expandan sus negocios. La mayoría de los principales actores se centran en países emergentes como India, China y otros debido al gran número de pacientes con cáncer y al crecimiento del turismo médico en los países en desarrollo. La mayoría de los países emergentes son lugares preferidos para el turismo médico.
Según Según el Instituto Australiano de Salud y Bienestar, en 2021 se diagnostican 151.000 nuevos casos de cáncer. Además, según el Consejo de Viajes de Atención Médica de Malasia, en 2020, más de 2 millones visitaron Malasia con fines sanitarios, lo que duplicó los ingresos por turismo médico a ~680 millones. Es probable que el bajo costo de las cirugías y las tecnologías avanzadas con menos tiempo de espera para los procedimientos en la región impulsen la demanda de biomarcadores del cáncer.
Por lo tanto, se prevé que el creciente turismo médico en los países emergentes y el aumento de la prevalencia del cáncer en Asia Pacífico brinden importantes oportunidades de crecimiento a los actores que operan en el mercado de biomarcadores del cáncer durante el período de pronóstico.< /span>
Información basada en tipos de biomarcadores
El mercado de biomarcadores de cáncer, según el tipo de biomarcador, se segmenta en biomarcadores genéticos, proteínas biomarcadores y otros. El segmento de biomarcadores de proteínas tuvo la mayor participación del mercado en 2022 y se prevé que registre la tasa de crecimiento más alta durante el período de pronóstico.
Mercado de biomarcadores del cáncer, por tipo de biomarcador: 2022 y 2028
Perfiles basados en tecnología
Perfiles basados en tecnología
El mercado de biomarcadores de cáncer, mediante tecnología de perfiles, se segmenta en tecnologías ómicas, tecnologías de imágenes, inmunoensayos, citogenética, y bioinformática. El segmento de tecnologías ómicas tuvo la mayor cuota de mercado en 2022 y se prevé que registre la mayor tasa de crecimiento entre 2022 y 2028.
Información basada en el tipo de cáncer
El mercado de biomarcadores de cáncer, según el tipo de cáncer, se segmenta en cáncer de mama, cáncer de pulmón, cáncer de próstata, leucemia, cáncer de vejiga y otros. En 2022, el otro segmento tenía la mayor cuota de mercado. Sin embargo, se espera que el segmento del cáncer de pulmón registre la tasa de crecimiento más rápida en los próximos años.
Información basada en aplicaciones
Según la aplicación, el mercado de biomarcadores de cáncer se segmenta en diagnóstico, investigación y desarrollo, pronóstico y otros. En 2022, el segmento de pronósticos ocupó la mayor cuota de mercado. Además, se prevé que el mismo segmento registre la CAGR más alta durante el período de pronóstico.
Las estrategias inorgánicas y orgánicas, como fusiones y adquisiciones, son altamente adoptadas por las empresas en el mercado de biomarcadores del cáncer. A continuación se enumeran algunos desarrollos clave recientes del mercado:
- En marzo de 2022, Vela Diagnostics lanzó una nueva secuenciación de próxima generación (NGS) enfocada (60 genes) e integral (525 genes). Paneles basados en ARN y ADN para detectar biomarcadores de cáncer a partir de muestras de tejido fijadas con formalina e incluidas en parafina (FFPE). Los nuevos paneles genéticos contra el cáncer incluyen el panel OncoKey SL 60 Plus enfocado y el completo panel OncoKey SL 525 Plus.
- En marzo de 2022, el Instituto Nacional del Cáncer, parte de los Institutos Nacionales de Salud, lanzó la Iniciativa de Caracterización Molecular para tumores pediátricos. Este programa ofrece caracterización molecular de tumores, también llamada prueba de biomarcadores, a niños, adolescentes y adultos jóvenes con tumores del sistema nervioso central recién diagnosticados que están siendo tratados en hospitales afiliados al Grupo de Oncología Infantil
- En diciembre de 2021 , BioGenex lanzó tres nuevos anticuerpos de inmunohistoquímica primaria (IHC), incluidos CD8A, CD163 y CD56, para el diagnóstico del cáncer.
- En mayo de 2021, GE Healthcare adquiere el fabricante de biomarcadores oncológicos Zionexa para seguir desarrollando agentes de imágenes moleculares para el tratamiento del cáncer. La empresa desarrollará y comercializará los biomarcadores Zionexa y el agente de obtención de imágenes para tomografía por emisión de positrones (PET), Cerianna (fluoroestradiol F-18). Cerianna está aprobado por la Administración de Drogas y Alimentos de EE. UU. para su uso como complemento de la biopsia para identificar lesiones positivas del receptor de estrógeno (RE). Puede ayudar a elegir las mejores terapias para pacientes con cáncer de mama recurrente o metastásico.
- En abril de 2021, Amgen lanzó Biomarker Assist, un programa para ayudar a más pacientes con cáncer de pulmón de células no pequeñas (NSCLC) metastásico (estadio IV). ) obtener acceso a pruebas de biomarcadores. Las pruebas de biomarcadores en el momento del diagnóstico son un primer paso fundamental para que los pacientes reciban el tratamiento adecuado. A través de Biomarker Assist, los pacientes elegibles pueden ahorrar en pruebas de biomarcadores.
Perfiles de empresa
- Thermo Fisher Scientific Inc
- F. Hoffmann-La Roche Ltd
- Illumina Inc
- Bio-Rad Laboratories Inc
- < span>QIAGEN
- bioMérieux Inc
- Creative Diagnostics Hologic Inc
- Myriad Genetic Inc
- Diagnóstico de misiones
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
National Cancer Institute defined biomarker as a biological molecule found in blood, or tissues or other body fluids that is a sign of a standard or abnormal process. A biomarker is employed to ascertain however well the body responds to a treatment for a malady or condition. Cancer biomarkers area unit the molecules that aid within the examination similarly because the treatment of various kinds of cancer. These molecules are often evaluated by aggregation samples like stool, neoplasm tissue, blood, urine, or alternative tissues or bodily fluids.
The key factors that are driving growth of the market are growing cancer prevalence across the globe, new product launches and FDA approvals, and technological advancements.
Unfavorable regulatory and reimbursement scenario is the major factor hindering the market growth.
Based on biomarker types, the protein biomarker segment held largest share of the market and protein biomarker segment is projected to register the highest CAGR during the forecast period.
The cancer biomarkers report contains forecast of 2019 to 2027.
The List of Companies
- Bio-Rad Laboratories, Inc.
- Thermo Fisher Scientific, Inc.
- F. Hoffmann-La Roche Ltd.
- QIAGEN N.V.
- Illumina, Inc.
- Myriad Genetics, Inc.
- Hologic Inc.
- Quest Diagnostics Incorporated
- bioMérieux SA
- Creative Diagnostics
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports
Apr 2024
Bioprocessing Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product (Instruments, and Consumables and Accessories), Scale of Operation (Commercial Operations and Clinical Operations), Process (Downstream Bioprocess and Upstream Bioprocess), Application (Monoclonal Antibodies, Vaccines, Recombinant Protein, Cell and Gene Therapy, and Others), End User (Biopharmaceutical Companies, Contract Manufacturing Organization, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)
Apr 2024
Bioproduction Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Product (Biologics and Biosimilars, Vaccines, Cell and Gene Therapies, Nucleic Acid Therapeutics, and Others), Application (Rheumatoid Arthritis, Hematological Disorders, Cancer, Diabetes, Cardiovascular Diseases, and Others), Equipment (Upstream Equipment, Downstream Equipment, Bioreactors, and Consumables and Accessories), End User (Biopharmaceutical Companies, Contract Manufacturing Organizations, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Apr 2024
ELISA Diagnostic Test Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Adoption (Human and Veterinary), Test Type (Sandwich ELISA, Indirect ELISA, Competitive ELISA, and Multiple & Portable ELISA), Application (Autoimmune Diseases, Infectious Diseases, Cancer Diagnosis, Protein Quantification, and Others), End User (Hospitals & Diagnostic Centers, Pharmaceutical & Biotechnology Companies, Veterinary Hospitals & Diagnostic Laboratories, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)
Apr 2024
Swine Diagnostics Market
Size and Forecasts (2022 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Product Type [Immunoassays Kits, PCR Kits, Hemagglutination Inhibition (HI), and Others], Sample Type (Blood, Oral Fluids, Nasal Swabs, Tissue Samples, and Others), Disease [African Swine Fever (ASF)/Classical Swine Fever (CSF), Respiratory Diseases, Porcine Circovirus, Porcine Epidemic Diarrhea, Swine Dysentery, and Others], End User (Veterinary Hospitals, Veterinary Clinics, and Other End Users), and Geography
Apr 2024
Microbial Identification Methods Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Method (Genotypic, Phenotypic, and Proteotypic), Type (Bacterial Identification System, Microbial Enumeration System, Bacterial Resistance Identification Systems, Microbiology Analyzer, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and Latin America)
Apr 2024
Biopharmaceuticals Market
Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type (Monoclonal Antibodies, Recombinant Vaccines, Conventional Vaccines, Recombinant Growth Factors, Purified Proteins, Recombinant Proteins, Recombinant Hormones, Recombinant Enzymes, Cell & Gene Therapies, Cytokines/Interferon/Interleukins, and Others) and Application (Oncology, Inflammatory & Infectious Disease, Autoimmune Disorders, Metabolic Disorders, Hormonal Disorders & Growth Failure, Cardiovascular Diseases, Neurological Diseases, and Others)
Apr 2024
GMP Cell Therapy Consumables Market
Forecast to 2028 - COVID-19 Impact and Global Analysis by Product (Kits, Reagents/Molecular Biology Reagents, Growth Factors/Cytokines and Interleukins, and Others), Cell Therapy (NK Cell Therapy, Stem Cell Therapy, T-Cell Therapy, and Others), Process (Cell Collection and Characterization/Sorting and Separation, Cell Culture and Expansion/Preparation, Cryopreservation, Cell Processing and Formulation, Cell Isolation and Activation, Cell Distribution/Handling, Process Monitoring and Control/Readministration/Quality Assurance, and Others), and End Use (Clinical, Commercial, and Research)